MedMira's HIV/Hepatitis C Rapid Test Selected by Centers for Disease Control and Prevention (CDC) for Collaborative Evaluation Program



    HALIFAX, June 9 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that the Centers for Disease Control and Prevention
(CDC) in the United States has selected the Company's Multiplo HIV/Hepatitis C
(HCV) Rapid Test to be a part of a program entitled "Opportunity to
Collaborate in the Evaluation of Rapid Diagnostic Tests for HIV and HCV".
    This program of the National Center for HIV/AIDS, Viral Hepatitis, STD,
and TB Prevention (NCHHSTP) at the Centers for Disease Control and Prevention
(CDC) of the Department of Health and Human Services (DHHS) will see
evaluations done in laboratories and in the field to determine the viability
of rapid tests for use in screening and/or diagnosis of HIV and HCV in the
United States. A number of rapid tests will be evaluated as part of the
program however Multiplo HIV/HCV will be the only combination rapid
flow-through test with the ability to deliver simultaneous results for HIV and
HCV.
    "We are very pleased that our Multiplo HIV/HCV test was selected for
evaluation in this important CDC program. International evaluations and
feedback from leading researchers have been very positive and we fully expect
that our proven technology platform will continue to exceed expectations as
part of this program," said Hermes Chan, CEO of MedMira Inc. "In today's
economy, where every healthcare budget is being closely scrutinized, a
multiple test makes the most sense. Multiplo is essentially a 2-in-1 test that
costs the healthcare provider less while delivering results faster than any
two single tests combined. It is a win-win for healthcare providers and their
patients."
    According to the CDC's latest reports, an estimated 1,106,400 people in
the United States are living with HIV, with approximately 21% unaware of their
status. Approximately 3.2 million persons in the United States have chronic
hepatitis C virus infection. About one quarter of HIV-infected persons in the
United States are also infected with hepatitis C virus.
    Chan continued," It is widely understood that more testing and more
people knowing their status significantly decreases the spread of diseases
like HIV and Hepatitis C. Multiplo simultaneously diagnoses HIV and Hepatitis
C from a single drop of specimen in just three minutes, increasing the number
of people who know their status for both HIV and Hepatitis C."
    Built on MedMira's award-winning, patented rapid diagnostic technology
platform, Multiplo HIV/HCV requires just one drop of whole blood, serum or
plasma to detect HIV and/or HCV infections. The 3-step procedure takes three
minutes to perform and yields instant results. No sophisticated laboratory
equipment or refrigeration is required, making the test ideally suited for a
broad range of testing environments, from hospital laboratories, to
point-of-care, to mobile outreach clinics and in the future over-the-counter.

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Andrea Young, MedMira, (902) 450-1588,
ayoung@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890